Utility of a novel HCV-NS4 antigen detection immunoassay for monitoring treatment of HCV-infected individuals with pegylated interferon α-2a

详细信息    查看全文

• 作者：Attallah ; Abdelfattah M. ; Shiha ; Gamal E. ; Abdel Malak ; Camelia A. ; Hagras ; Hytham E. ; Abdel-Razik ; Waleed S. ; et. al.
• 关键词：HCV ; NS4 antigen ; Immunoassay ; Pegylated ; Interferon ; Therapy ; Response
• 刊名：Hepatology Research
• 出版年：2004
• 出版时间：February, 2004
• 年：2004
• 卷：28
• 期：2
• 页码：68-72
• 全文大小：72.3 K

文摘

Hepatitis C virus (HCV) infection continues to be an emerging global health concern. With the advent of additional treatment protocols, a simple and reliable assay for changes in HCV load may permit more frequent patient assessment and tailoring of the therapeutic regimen. Recently, we have developed a highly sensitive and specific enzyme immunoassay (EIA) for the detection of an HCV-Nonstructural 4 (NS4) antigen in serum. Here, we evaluated the efficacy of the developed assay in monitoring the virologic responses to pegylated interferon α-2a. Thirty-six (HCV genotype IV) out of 150 initially screened chronic HCV patients met the entry criteria and randomly (in a 1:2 ratio) assigned to receive monotherapy with peginterferon α-2a (Pegasys) or combined therapy of peginterferon α-2a plus ribavirin; respectively. No significant differences (P>0.05) were shown between the virologic responses defined by standard PCR-based HCV RNA testing and those defined by EIA-based HCV-NS4 antigen detection either at the end of treatment (week 24) or at the end of follow-up (week 48). Sustained virologic responses defined by the HCV-NS4 antigen in combined therapy patients were significantly higher (P<0.05) than those in monotherapy patients. In conclusion, the HCV-NS4 antigen as an alternative direct marker of HCV infection may be suitable for use in monitoring HCV-infected patients.